Numab Therapeutics AG

Numab Therapeutics is a Swiss clinical-stage biotechnology company focused on the discovery and development of next-generation, multispecific antibody-based immunotherapies for inflammation and cancer. The company utilizes its proprietary plug-and-play technology platforms, λ-Cap™ and MATCH™, to engineer highly stable, multispecific antibody fragments with tailored pharmacokinetic properties. Numab operates through a business model that combines an internal pipeline of first-in-class and best-in-class candidates with strategic research collaborations and licensing agreements with major pharmaceutical partners. The company has demonstrated significant success in its platform validation, notably through the 2024 acquisition of its subsidiary Yellow Jersey Therapeutics by Johnson & Johnson for $1.25 billion, which secured rights to the lead atopic dermatitis candidate, NM26.